632 results on '"Korobelnik, Jean-François"'
Search Results
2. XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
3. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
4. Association of Lipopolysaccharide-Type Endotoxins with Retinal Neurodegeneration: The Alienor Study
5. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
6. Associations of circulating vitamins with 10-year retinal neurodegeneration: the Alienor Study
7. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
8. LIFETIME AMBIENT ULTRAVIOLET RADIATION EXPOSURE AND INCIDENCE OF AGE-RELATED MACULAR DEGENERATION
9. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
10. Association of long-term exposure to ambient air pollution with retinal neurodegeneration: the prospective Alienor study
11. Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus
12. The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus
13. Randomized Phase 2b Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-related Macular Degeneration
14. Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema
15. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
16. Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure
17. DeepAlienorNet: A deep learning model to extract clinical features from colour fundus photography in age‐related macular degeneration.
18. Associations of drusen location with risk factors and incidence of late age‐related macular degeneration in the Alienor study.
19. Retinal microvasculature and risk of incident dementia over a 10‐year period: results from the 3C‐Alienor population‐based study
20. Faricimab Treat-and-Extend for Diabetic Macular Edema
21. Quantitative Analysis of Radial Peripapillary Capillary Network in Patients With Papilledema Compared with Healthy Subjects Using Optical Coherence Tomography Angiography
22. Quantitative Analysis of Radial Peripapillary Capillary Network in Patients With Papilledema Compared with Healthy Subjects Using Optical Coherence Tomography Angiography
23. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
24. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study
25. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies
26. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies
27. Retinal microvasculature and incident dementia over 10 years: The Three‐City‐Alienor cohort
28. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
29. Ambient air pollution exposure and incidence of cataract surgery: the prospective 3City-Alienor study
30. Ophthalmologic Phenotype–Genotype Correlations in Patients With Oculocutaneous Albinism Followed in a Reference Center
31. Management of retinal pigment epithelium tear during anti-VEGF therapy
32. Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies
33. Adapted Surgical Procedure for Argus II Retinal Implantation: Feasibility, Safety, Efficiency, and Postoperative Anatomic Findings
34. INCIDENCE, PROGRESSION, AND RISK FACTORS OF EPIRETINAL MEMBRANES IN THE ELDERLY
35. Association of retinal nerve layers thickness and brain imaging in healthy young subjects from the i‐Share‐Bordeaux study
36. P23-054-23 Serum Vitamins and Retinal Nerve Fiber Layer Changes on SD-OCT: The Alienor Study
37. Case report of Susac syndrome, ophthalmologic description and therapeutic escalation
38. ADVERSE EVENTS OF THE ARGUS II RETINAL PROSTHESIS: Incidence, Causes, and Best Practices for Managing and Preventing Conjunctival Erosion
39. LIFELONG PROGRESSIVE RETINAL ATROPHIC LESIONS IN A PATIENT WITH PARTIAL ACQUIRED LIPODYSTROPHY (BARRAQUER–SIMONS SYNDROME)
40. Ophthalmic epidemiology in Europe: the "European Eye Epidemiology" (E3) consortium
41. Associations with intraocular pressure across Europe: The European Eye Epidemiology (E³) Consortium
42. ADVERSE EVENTS OF THE ARGUS II RETINAL PROSTHESIS: Incidence, Causes, and Best Practices for Managing and Preventing Conjunctival Erosion
43. Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases
44. Fluocinolone acetonide implant (Iluvien®) for macular edema associated with retinitis pigmentosa: A case report.
45. Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus.
46. Diabetic retinopathy relates to the incidence of foot ulcers and amputations in type 2 diabetes
47. Optical Coherence Tomography Angiography in Diabetic Macular Edema Treated with Intravitreal Aflibercept: A 48-Week Observational Study (the DOCTA Study)
48. Mydriatic insert and intracameral injections compared with mydriatic eyedrops in cataract surgery: Controlled studies
49. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome
50. Fluocinolone acetonide implant (Iluvien®) for macular edema associated with retinitis pigmentosa: A case report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.